Difference between revisions of "Adrenocortical carcinoma - null regimens"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
||
| Line 10: | Line 10: | ||
|} | |} | ||
===Regimen=== | ===Regimen=== | ||
| − | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Revision as of 02:54, 26 September 2020
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for current regimens.
Recurrent, locally advanced, or metastatic disease
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Fassnacht et al. 2015 (GALACCTIC) | 2009-2011 | Phase III (C) | Linsitinib | Did not meet primary endpoint of OS |
No active antineoplastic treatment.
References
- GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed NCT00924989